Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,632 shares of the company’s stock in a transaction on Friday, January 8th. The stock was sold at an average price of $111.06, for a total transaction of $292,309.92. Following the transaction, the insider now owns 15,845 shares of the company’s stock, valued at approximately $1,759,745.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Neurocrine Biosciences stock opened at $108.15 on Thursday. The firm has a market capitalization of $10.10 billion, a P/E ratio of 116.29 and a beta of 1.00. Neurocrine Biosciences, Inc. has a 1-year low of $72.14 and a 1-year high of $136.26. The company’s 50-day moving average is $97.98 and its 200 day moving average is $106.30.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Saturday, November 14th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.73). Neurocrine Biosciences had a net margin of 8.96% and a return on equity of 18.18%. The business had revenue of $258.80 million for the quarter, compared to the consensus estimate of $282.59 million. During the same period in the prior year, the company posted $0.56 EPS. The company’s quarterly revenue was up 16.5% compared to the same quarter last year. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 1.28 EPS for the current year.
Several analysts have commented on the stock. Morgan Stanley decreased their price target on shares of Neurocrine Biosciences from $133.00 to $121.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 16th. Mizuho dropped their price target on Neurocrine Biosciences from $132.00 to $117.00 and set a “neutral” rating for the company in a research note on Tuesday, November 10th. Smith Barney Citigroup cut their price target on Neurocrine Biosciences from $149.00 to $138.00 in a report on Tuesday, November 10th. Canaccord Genuity decreased their price objective on Neurocrine Biosciences from $145.00 to $122.00 and set a “buy” rating on the stock in a report on Thursday, November 12th. Finally, Benchmark assumed coverage on shares of Neurocrine Biosciences in a report on Wednesday, September 30th. They issued a “hold” rating for the company. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $127.45.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc, a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis.
Featured Story: Risk Tolerance
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.